Bedrijfsoverzicht
Allurion Technologies Inc. is a medical device manufacturer dedicated to addressing obesity through a specialized weight loss platform designed for individuals who are overweight. The company operates within the healthcare sector, specifically in the medical devices industry, where it develops and distributes innovative intragastric solutions that do not require surgical procedures. This enterprise employs a workforce of 38 individuals and currently holds a market capitalization of $12.45 million while reporting annual revenue of $15.23 million. The relatively small market cap combined with the modest revenue figure and low employee count indicates that Allurion is a micro-cap entity operating with a niche product focus rather than broad market dominance, suggesting a high-risk profile typical of early-stage biotech or medical device firms seeking to validate their technology in a competitive therapeutic space.
Financiële gezondheid
The company generated revenue of $15.23 million over the trailing twelve months, yet reported a net income of -$28,755,000, revealing a significant disconnect between top-line sales and profitability that points to an aggressive cost structure or substantial one-time expenses eroding margins. The enterprise's EBITDA stands at -$29,174,000, while free cash flow is negative at -$16,837,124, which indicates a severe lack of financial flexibility and a reliance on external capital sources to fund operations and capital expenditures. Despite generating positive gross margins of 62.8%, the operating margin is negative at -174.2% and the profit margin is even more distressed at -188.8%, highlighting that general and administrative expenses or research costs are vastly exceeding the value captured from product sales. On the balance sheet, the company holds $5.41 million in cash but carries $76.74 million in debt, resulting in a debt-to-equity ratio listed as N/A due to the negative equity position, which suggests a highly leveraged and precarious financial state rather than a conservative approach to capital management. The current ratio is calculated at 0.33, a figure that signals severe short-term liquidity constraints as current liabilities significantly outweigh current assets. Return on Equity is N/A because the company has negative shareholders' equity, and Return on Assets is -77.6%, demonstrating that management is currently generating substantial losses on the asset base rather than creating value for investors.
Waarderingsbeoordeling
Valuation metrics for Allurion present a complex picture where the trailing P/E ratio is N/A due to losses, while the forward P/E is -0.67, implying that the market expects earnings to remain negative or that the valuation model relies on future recovery rather than current profitability. The price-to-book ratio is listed at -0.13, a negative figure indicating that the market values the company well below its book value, which is often a signal of distressed assets or negative shareholder equity rather than a standard market premium. Alternative valuation metrics such as the price-to-sales ratio of 0.82 and an EV/EBITDA of -2.87 suggest that the market is pricing the stock based on sales multiples rather than earnings power, a common practice for pre-profitability medical device companies. The stock has traded between a 52-week low of $0.23 and a 52-week high of $3.42, meaning the current share price fluctuates within a highly volatile range that reflects extreme uncertainty about future commercialization success. The beta of -0.25 is an anomalous statistic that implies the stock price moves in an inverse relationship to the broader market or that the calculation methodology for this specific micro-cap yields an atypical volatility measure that does not align with standard market risk models.
Growth & Income
Revenue growth year-over-year has contracted by 35.4%, while earnings growth is N/A, indicating that the company is currently in a decline phase regarding sales volume rather than a period of expansion. The fact that earnings growth cannot be calculated alongside negative earnings suggests that the company is not generating profit to reinvest, and consequently, there is no dividend yield or payout ratio to evaluate for income investors. Since the company does not pay dividends, it is forced to retain its limited cash reserves, though the negative free cash flow suggests it is burning through capital rather than reinvesting earnings into organic growth. The overall growth and income profile is characterized by declining sales, significant operational losses, and a complete absence of shareholder returns, positioning Allurion as a speculative investment focused entirely on potential future product adoption rather than current financial performance or dividend income.